This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
(‘Reprieve’), a development stage company focused on pioneering an intelligent approach to acute decompensated heartfailure (ADHF) treatment, today highlighted the publication of TREAT-AHF study results in JACC: HeartFailure. Heartfailure (HF) is a leading cause of hospitalization in the United States.
mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heartfailure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with HeartFailure with Preserved Ejection Fraction (HFpEF).
I had the impression throughout the past year that it's clearly unusual for the British Medical Journal (BMJ) to invite a heart patient (who is not a doctor, a researcher or an academic) to write an Editorial for BMJ Open Heart - but it's just been published!!
The inherited heart condition often goes undiagnosed until it advances to heartfailure, which is why it’s important to identify those at risk and begin treatment early. Hershberger leads the DCM Consortium , which is composed of 25 leading academic U.S. Eventually heartfailure may develop, which is late-phase disease.
Objective This study aimed to investigate the association between heartfailure (HF) severity measured based on brain natriuretic peptide (BNP) levels and future bleeding events after percutaneous coronary intervention (PCI).
The clinical role and educational preparation of heartfailure nurses across Europe. HF, heartfailure; HFN, heartfailure nurse; MDT, multidisciplinary team. The majority of nurses surveyed were committed to further academic professional development, with 41% ( n = 343) having completed a HF course.
Photo courtesy of Wake Forest University School of Medicine milla1cf Thu, 02/22/2024 - 13:51 February 22, 2024 — Wake Forest University School of Medicine , the academic core of Advocate Health , is expanding another research study to Advocate Christ Medical Center , in Oak Lawn, Illinois, just outside Chicago.
Henry Ford Health's Center for Structural Heart Disease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heartfailure patient on February 13, 2024 at Henry Ford Hospital in Detroit. Medical Director of Structural Heart Disease at Henry Ford Health. “We
Ischemic heart disease (IHD) is one of the world's foremost killers, accounting for 16% of all deaths worldwide. IHD is the main cause of heartfailure (HF), as it leads to pathological changes in the heart, improper pumping function and eventual death.
The expertise of our clinicians, like Dr. Saybolt, enables our academic medical center to provide these leading-edge clinical trials. Our program continues to grow as more of our neighbors select the academic medical center to receive exemplary health care,” said Kenneth N.
Clinical parameters were acquired from database of Academic Repository of Clinical Cases of Medical University of Silesia. females) with different cardiovascular disorders and at least two measurements of LVEF separated by 1 month. HFimpEF was defined by LVEF increase 10% in HF patients in relation to baseline value.
Aims Iron deficiency (ID) is common in patients with heartfailure (HF) and is associated with poor outcomes, regardless of anaemia status. Cardiologists' age, training status, subspecialty and work setting (academic vs. non-academic hospitals) were associated with heterogeneity in the answers.
David Austin, MD “We did not see evidence that we could reduce this biomarker of cardiotoxicity during chemotherapy [with an ACE inhibitor],” said David Austin, MD , consultant cardiologist at the academic cardiovascular unit in James Cook University Hospital , South Tees, Middlesbrough, United Kingdom, and the study’s lead author.
Stone , Director of Academic Affairs for the Mount Sinai Health System and Professor of Medicine (Cardiology), and Population Health Science and Policy, at the Icahn School of Medicine at Mount Sinai (New York, USA) will be the Principal Investigator of the Pivotal study.
We know that structural heart disease and heartfailure are the leading causes of hospitalization and morbidity in the U.S. CARDIO was trained on hundreds of thousands of studies comprising over 24 million echo video clips.
The researchers set out to solve this problem using AI, and indeed showed that AI could perform MR exams at the same level as academic echo labs. Transthoracic echocardiography is the go-to modality for mitral regurgitation diagnosis, but these exams are difficult to perform and prone to high variability.
During conduct of the REALIZE-K Trial, Dr. Mikhail Kosiborod acted as the PI from an independent academic research organization; he was not an employee of AstraZeneca during the design or conduct of REALIZE-K Trial or at the time of manuscript submission.
There is less compelling academic reasons for this change, than we think. It is worth-while to wait, watch and think before we adopt this modality for mass consumption in heartfailure with wide qrs LBBB.
So imagine my surprise when I saw peer reviewed research based on a cardiac MRI study come out in 2020 suggesting that 78% of patients who survived COVID may have significant heart damage. The article and authors were more suited as writers for Oprah and Dr. Phil than a well respected academic journal. I have no idea.
The open-data movement seeks to liberate the massive amount of data generated in running clinical trials from the grasp of the academic medical-pharmaceutical industrial complex that mostly runs the most important trials responsible for bringing novel therapeutics to market. But first, some background.
Investigators assessed if empagliflozin could lower the risk of hospitalization for heartfailure (HF) or death from cardiovascular disease (CVD). The primary superiority endpoint was clinically relevant bleeding (Bleeding Academic Research Consortium [known as BARC] types 2, 3, or 5).
He denied any known medical history, specifically: coronary artery disease, hypertension, dyslipidemia, diabetes, heartfailure, myocardial infarction, or any prior PCI/stent. Breath sounds were clear in all lung fields. No appreciable skin pallor. He reported to be a social drinker, but used tobacco products daily.
More evidence this past week that vaccine myocarditis is very much a real entity while COVID19 myocarditis is mostly a fabrication of academic researchers comes from Scandinavian countries. Subscribe for free to receive new posts and support my work. Notice that there is no spike in myocarditis diagnoses until the second half of 2021.
In the interest of academic discussion Ill present a nother p erspective on selected aspects this case. Given the heartfailure and markedly abnormal ECGs I would expect cardiac cath at some point to have been performed. I schemic H eart D isease can be recent or longstanding. Has this patient been cathed?
NT-pro-BNP peaked at 4831, consistent with heartfailure. This distinction is more than academic — because both treatment and the response to therapy tend to be different with these 2 entities. The patient was referred for coronary angiography which did not reveal any atherosclerotic changes. Troponin I peaked at 769 ng/L.
Anuradha Lala-Trindade, MD: She focuses on the selection and care of patients with mechanical circulatory support devices and heart transplantation, genetic cardiomyopathies, and perioperative management of high-risk cardiac surgical cases. A framework for mentor-mentees can help promote and retain women in academic medicine.
This is one case where it made a difference: Right Ventricular MI seen on ECG helps Angiographer to find Culprit Lesion Nevertheless, it is sometimes a fun academic exercise to try to predict the infarct artery: An elderly patient had onset of chest pain one hour prior. He called 911. Here is the prehospital ECG. What do you think?
It is interesting particularly because the ensconced narrative in academic circles and the medically related twitterati that seem to have an outsized influence on COVID related policy has been that vaccine myocarditis is “mild” Leo Lam, Ph.D.💉⚕️🌎🇺🇸🇬🇧🏴🇭🇰
5 "These risk factors are associated with an increased risk of premature coronary artery disease, premature heartfailure, premature stroke and premature mortality in women," adds Sharma. After menopause, when protective estrogen levels drop, women's cardiovascular risk rises dramatically.5 It's really empowering to the patient."
History of Cardiovascular disease (all studies): Especially any history of heartfailure or structural cardiac disease, including valvular 4. Academic Emergency Medicine., h/o heart disease (+1) 3. Academic Emergency Medicine, 2003 Volume 10, Number 5 539-540. Age greater than 65 (Sarasin and STePS) 3. Mukarram, M.,
In fact, 25 percent of cardiac patients over 80 will likely have a form of amyloidosis in their hearts; 13 percent of patients with heartfailure have amyloid proteins in their systems and 3.5 Without proper care the average life expectancies for AL amyloidosis and ATTR amyloidosis patients are 6 months and 2.6
At one point George Mann attempted to arrange a meeting of scientists who agreed that the diet-heart/cholesterol hypothesis was bunk. I believe you are right, and that the diet-heart hypothesis is wrong, but I cannot join you, for that would jeopardize my perks and funding. SEARCH trial of simvastatin dose (1997-2010) Merck: £22.7M
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
105 
Let's personalize your content